916889-45-7 Usage
Uses
Used in Pharmaceutical Industry:
Ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and biological activity make it a promising candidate for drug discovery and development.
Used in Agrochemical Industry:
Ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate is used as a building block for the synthesis of various agrochemicals. Its diverse chemical reactivity allows for the development of new and effective agrochemicals.
Used in Functional Materials:
Ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate is used as a building block for the synthesis of functional materials. Its unique structure and properties contribute to the development of advanced materials with specific applications.
Used in Organic Synthesis:
Ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate is used as a reagent in organic synthesis. Its diverse chemical reactivity allows for the formation of various compounds and contributes to the advancement of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 916889-45-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,8,8 and 9 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 916889-45:
(8*9)+(7*1)+(6*6)+(5*8)+(4*8)+(3*9)+(2*4)+(1*5)=227
227 % 10 = 7
So 916889-45-7 is a valid CAS Registry Number.
916889-45-7Relevant academic research and scientific papers
AZACYCLOPENTANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
-
Page/Page column 47-48, (2008/06/13)
Azacyclopentane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis.
